Treatment with bone morphogenetic protein 2 limits infarct size after myocardial infarction in mice

Shock

Volumn 39, Issue 4, 2013, Pages 353-360

  Ebelt, Henning ^a   Hillebrand, Ina ^a   Arlt, Stephan ^a   Zhang, Ying ^a   Kostin, Sawa ^b   Neuhaus, Herbert ^a   Müller Werdan, Ursula ^a   Schwarz, Elisabeth ^a   Werdan, Karl ^a   Braun, Thomas ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

apoptosis; BMP 2; cardiomyocytes; myocardial infarction

Indexed keywords

ADENOSINE TRIPHOSPHATE; BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PACING; HEART WORK; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; MESODERM; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY;

ANIMALS; APOPTOSIS; BENZAMIDES; BONE MORPHOGENETIC PROTEIN 2; CARDIOTONIC AGENTS; CELL HYPOXIA; DIOXOLES; ECHOCARDIOGRAPHY; INJECTIONS, INTRAVENOUS; MICE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECOMBINANT PROTEINS; SMAD PROTEINS;

EID: 84875369230     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318289728a     Document Type: Article

References (36)

1. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, Czer LS, Marban L, Mendizabal A, Johnston PV, et al.: Intracoronary cardiospherederived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 379:895-904, 2012.
2. Schultheiss TM, Burch JB, Lassar AB: A role for bone morphogenetic proteins in the induction of cardiac myogenesis. Genes Dev 11:451-462, 1997. (Pubitemid 27097644)
3. Callis TE, Cao D, Wang DZ: Bone morphogenetic protein signaling modulates myocardin transactivation of cardiac genes. Circ Res 97:992-1000, 2005. (Pubitemid 41668912)
4. Wu J, Kubota J, Hirayama J, Nagai Y, Nishina S, Yokoi T, et al.: p38 Mitogenactivated protein kinase controls a switch between cardiomyocyte and neuronal commitment of murine embryonic stem cells by activating myocyte enhancer factor 2C-dependent bone morphogenetic protein 2 transcription. Stem Cells Dev 19:1723-1734, 2010.
5. Zhang H, Bradley A: Mice deficient for BMP-2 are nonviable and have defects in amnion/chorion and cardiac development. Development 122:2977-2986, 1996. (Pubitemid 26371964)
6. Izumi M, Fujio Y, Kunisada K, Negoro S, Tone E, Funamoto M, et al.: Bone morphogenetic protein-2 inhibits serum deprivation-induced apoptosis of neonatal cardiac myocytes through activation of the Smad1 pathway. J Biol Chem 276:31133-31141, 2001.
7. Ghosh-Choudhury N, Abboud SL, Chandrasekar B, Ghosh Choudhury G: BMP-2 regulates cardiomyocyte contractility in a phosphatidylinositol 3 kinasedependent manner. FEBS Lett 544:181-184, 2003. (Pubitemid 36628058)
8. Masaki M, Izumi M, Oshima Y, Nakaoka Y, Kuroda T, Kimura R, et al.: Smad1 protects cardiomyocytes from ischemia-reperfusion injury. Circulation 111:2752-2759, 2005. (Pubitemid 40791546)
9. Hillger F, Herr G, Rudolph R, Schwarz E: Biophysical comparison of BMP-2, ProBMP-2, and the free pro-peptide reveals stabilization of the pro-peptide by the mature growth factor. J Biol Chem 280:14974-14980, 2005. (Pubitemid 40562849)
10. Katagiri T, Yamaguchi A, Ikeda T, Yoshiki S, Wozney JM, Rosen V, et al.: The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. Biochem Biophys Res Commun 172:295-299, 1990. (Pubitemid 20352535)
11. Muller-Werdan U, Klein D, Zander M, Werdan K, Hammer C: Beating neonatal rat cardiomyocytes as a model to study the role of xenoreactive natural antibodies in xenotransplantation. Transplantation 58:1403-1409, 1994.
12. Schafer M, Ponicke K, Heinroth-Hoffmann I, Brodde OE, Piper HM, Schluter KD: Beta-adrenoceptor stimulation attenuates the hypertrophic effect of alphaadrenoceptor stimulation in adult rat ventricular cardiomyocytes. J Am Coll Cardiol 37:300-307, 2001. (Pubitemid 32051754)
13. Kubin T, Vogel S, Wetzel J, Hein S, Pipp F, Herold J, et al.: Porcine aortic endothelial cells show little effects on smooth muscle cells but are potent stimulators of cardiomyocyte growth. Mol Cell Biochem 242:39-45, 2003. (Pubitemid 36240527)
14. Muller-Werdan U, Schumann H, Fuchs R, Reithmann C, Loppnow H, Koch S, et al.: Tumor necrosis factor alpha (TNF alpha) is cardiodepressant in pathophysiologically relevant concentrations without inducing inducible nitric oxide- (NO)-synthase (iNOS) or triggering serious cytotoxicity. J Mol Cell Cardiol 29:2915-2923, 1997. (Pubitemid 27510758)
15. Korte T, Fuchs M, Guener Z, v Bonin J, de Sousa M, Niehaus M, et al.: In-vivo electrophysiological study in mice with chronic anterior myocardial infarction. J Interv Card Electrophysiol 6:121-132, 2002. (Pubitemid 34594833)
16. Kostin S, Pool L, Elsasser A, Hein S, Drexler HC, Arnon E, et al.: Myocytes die by multiple mechanisms in failing human hearts. Circ Res 92:715-724, 2003. (Pubitemid 36457635)
17. Fuchs M, Hilfiker A, Kaminski K, Hilfiker-Kleiner D, Guener Z, Klein G, et al.: Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. FASEB J 17:2118-2120, 2003.
18. Pelzer T, Loza PA, Hu K, Bayer B, Dienesch C, Calvillo L, et al.: Increased mortality and aggravation of heart failure in estrogen receptor-beta knockout mice after myocardial infarction. Circulation 111:1492-1498, 2005. (Pubitemid 40470643)
19. Ebelt H, Braun T: Optimized, highly efficient transfer of foreign genes into newborn mouse hearts in vivo. Biochem Biophys Res Commun 310: 1111-1116, 2003. (Pubitemid 37237651)
20. Ebelt H, Jungblut M, Zhang Y, Kubin T, Kostin S, Technau A, et al.: Cellular cardiomyoplasty: improvement of left ventricular function correlates with the release of cardioactive cytokines. Stem Cells 25:236-244, 2007. (Pubitemid 46052995)
21. Chen D, Zhao M, Mundy GR: Bone morphogenetic proteins. Growth Factors 22:233-241, 2004. (Pubitemid 40136452)
22. Pashmforoush M, Lu JT, Chen H, Amand TS, Kondo R, Pradervand S, et al.: Nkx2-5 pathways and congenital heart disease: loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block. Cell 117:373-386, 2004. (Pubitemid 38534543)
23. Euler-Taimor G, Heger J: The complex pattern of SMAD signaling in the cardiovascular system. Cardiovasc Res 69:15-25, 2006. (Pubitemid 41814808)
24. Nakajima H, Nakajima HO, Salcher O, Dittie AS, Dembowsky K, Jing S, et al.: Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. Circ Res 86:571-579, 2000. (Pubitemid 30165049)
25. Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, et al.: TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109:787-796, 2002. (Pubitemid 34263155)
26. Wang S, Sun A, Li L, Zhao G, Jia J, Wang K, et al.: Upregulation of BMP-2 antagonizes TGF-beta1/ROCK-enhanced cardiac fibrotic signaling through activating of Smurf1/Smad6 complex. J Cell Mol Med 16:2301-2310, 2012.
27. Hao J, Wang B, Jones SC, Jassal DS, Dixon IM: Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol Heart Circ Physiol 279:H3020-H3030, 2000. (Pubitemid 32005893)
28. Candia AF,Watabe T, Hawley SH, Onichtchouk D, Zhang Y, Derynck R, et al.: Cellular interpretation of multiple TGF-beta signals: intracellular antagonism between activin/BVg1 and BMP-2/4 signaling mediated by Smads. Development 124:4467-4480, 1997. (Pubitemid 27519243)
29. Kostin S: Pathways of myocyte death: implications for development of clinical laboratory biomarkers. Adv Clin Chem 40:37-98, 2005. (Pubitemid 43588720)
30. Zou H, Niswander L: Requirement for BMP signaling in interdigital apoptosis and scale formation. Science 272:738-741, 1996. (Pubitemid 26152785)
31. Zhao Z, Rivkees SA: Programmed cell death in the developing heart: regulation by BMP-4 and FGF2. Dev Dyn 217:388-400, 2000. (Pubitemid 30185562)
32. Huang J, Nakamura K, Ito Y, Uzuka T, Morikawa M, Hirai S, et al.: Bcl-xL gene transfer inhibits Bax translocation and prolongs cardiac cold preservation time in rats. Circulation 112:76-83, 2005. (Pubitemid 40962572)
33. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P: Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 21:1743-1753, 2002. (Pubitemid 34614630)
34. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, et al.: Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 97:2626-2631, 2000. (Pubitemid 30159221)
35. Konig HG, Kogel D, Rami A, Prehn JH: TGF-{beta}1 activates two distinct type I receptors in neurons: implications for neuronal NF-{kappa}B signaling. J Cell Biol 168:1077-1086, 2005.
36. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, et al.: SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62:65-74, 2002. (Pubitemid 34680517)